

Submitted by: Brian Alexander, MD
Company: Foundation Medicine, Inc.
Address: 150 Second Street, Cambridge, MA 02141
Phone: 617-418-2200 Ext. 2256
Email: baalexander@foundationmedicine.com
Date of request: September 18, 2020
NCCN Guidelines Panel: CNS Cancers

Dear Panel Members,

On behalf of Foundation Medicine, I respectfully request the NCCN® Central Nervous System Cancers Guideline Panel consider the requested updates pertaining to the evaluation and management of patients with CNS cancers.

Requested Updates:

1. **Add tumor mutational burden (TMB) testing by an FDA approved and/or validated assay under “tumor agnostic” on BRAIN-D 8 of 15 and add sub-bullet for pembrolizumab.**
2. **Add footnotes for TMB validation standards (as published in Merino et al 2020) and pembrolizumab as a treatment option for patients with unresectable or metastatic tumors with tissue tumor mutational burden-high (tTMB-H) ≥ 10 mutations/megabase, as determined by an FDA-approved test, who have progressed following prior treatment and who have no satisfactory alternative treatment options. (BRAIN-D 8 of 15)**

Rationale for Requested Updates:

KEYNOTE-158 (NCT02628067) was a multicohort, single-arm, open-label phase 2 study evaluating pembrolizumab monotherapy in 1066 patients with selected previously treated advanced solid tumors, who were administered pembrolizumab 200 mg once every 3 weeks by intravenous infusion¹. 805/1066 patients had an evaluable tissue TMB (tTMB) score (efficacy population), and 105 (13%) were tTMB-high, defined as ≥ 10 mutations/megabase per the FoundationOne CDx panel, and were assessed for safety. 1050 (98%) of 1066 patients enrolled by at least 26 weeks before data cutoff, of whom 790 (75%) were evaluable for TMB and included in efficacy analyses. 102 (13%) of 790 patients had tTMB-high status. tTMB-high status was associated with a clinically meaningful improvement as demonstrated by an objective response rate (ORR) of 29% (95% CI, 21-39), compared to 6% (95% CI, 5-8) in the non-tTMB-high group (primary endpoint). Median follow-up was 37.1 months (IQR 35.0-38.3) and median duration of response was not reached in the tTMB-high group and was 33.1 months in the non-tTMB-high group. Additional secondary outcomes at landmark timepoints include the 2-year PFS rate of 22% (95% CI 14-30) in the tTMB-high group vs. 7% (95% CI 5-9) in the non-tTMB-high group, and the 3-year OS rate of 32% (95% CI 23-41) in the tTMB-high group versus 22% (95% CI 19-25) in the non-tTMB-high group. The predictive value of tTMB was independent of other biomarkers, including microsatellite instability (MSI)-high and PD-L1 expression. Additionally, the predictive value of tTMB did not appear to be driven by a particular tumor type, with an increased response rate for TMB-high patients observed across most tumor types. Based on the results of KEYNOTE-158, pembrolizumab is now FDA-approved for patients with unresectable or metastatic solid tumors with tTMB-high (≥ 10 mutations/megabase), as determined by an FDA-approved test, who have progressed following prior treatment and who have no satisfactory alternative treatment options^{2,3}.

TMB is a complex continuous biomarker and TMB estimation provided by next generation sequencing (NGS) targeted panels can vary across laboratories due to factors such as differences in panel size, gene coverage, and bioinformatics pipelines. Because of the important role TMB now plays in clinical decision-making and the potential for variation across laboratories, the Friends of Cancer Research convened a consortium of key stakeholders to recommend best practices and approaches for TMB measurement, validation, alignment and reporting⁴. Stakeholders, including the FDA, the National Cancer Institute, diagnostic manufacturers, academics, and pharmaceutical companies published detailed recommendations around TMB reporting consistency, standardization of analytical validation studies for TMB estimation, and alignment of panel TMB values to a whole exome sequencing (WES)-derived universal reference standard⁴. All tests that report a TMB value should comply with the recommendations as published and/or be FDA-approved for TMB measurement and reporting purposes^{3,5}.

Thank you for your review of this submission.

Sincerely,

A handwritten signature in black ink, appearing to read 'BA', followed by a long horizontal flourish.

Brian Alexander, M.D.
Chief Medical Officer
Foundation Medicine

References

1. Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study [published online ahead of print, 2020 Sep 10]. *Lancet Oncol*. 2020;S1470-2045(20)30445-9.
2. KEYTRUDA (pembrolizumab) FDA approved label found at https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf
3. FDA Label: Foundation Medicine Inc. FoundationOne® CDx Technical Information. (attached)
4. Merino DM, McShane LM, Fabrizio D, et al. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. *J Immunother Cancer* 2020;8:e000147.
5. Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. *Genome Med*. 2017;9(1):34. Published 2017 Apr 19. doi:10.1186/s13073-017-0424-2